Fig. 3.

Effects of haloperidol, ziprasidone, and placebo on ICU delirium or coma. In a randomized clinical trial of 566 ICU patients receiving haloperidol, ziprasidone, or placebo for treatment of hypoactive or hyperactive delirium, there were no significant differences among groups in days with delirium, days with coma, or days alive without delirium or coma. These analyses were adjusted for age, pre-existing cognitive impairment, Clinical Frailty Score and Charlson Comorbidity Index score at baseline, and modified Sequential Organ Failure Assessment score and Richmond Agitation–Sedation Scale score at randomization. ICU, intensive care unit. Reproduced with permission from Girard et al.²⁰